Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd is set to present new clinical data from its Phase IIb TACTI-003 trial at the ESMO Virtual Plenary, highlighting promising results in treating PD-L1 negative head and neck squamous cell carcinoma with their novel immunotherapy. The company will also host a webcast to further discuss these findings, which demonstrate significant therapeutic progress in an area of high unmet need. Immutep’s eftilagimod alfa, combined with pembrolizumab, has shown enhanced overall response rates in patients, warranting the attention of investors and stakeholders.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
